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Abstract
Increasing evidence has pointed to an important role of SUMOylation in cell cycle regulation, especially for M phase. In the
current studies, we have obtained evidence through in vitro studies that the master M phase regulator CDK1/cyclin B kinase
phosphorylates the SUMOylation machinery component Ubc9, leading to its enhanced SUMOylation activity. First, we show
that CDK1/cyclin B, but not many other cell cycle kinases such as CDK2/cyclin E, ERK1, ERK2, PKA and JNK2/SAPK1,
specifically enhances SUMOylation activity. Second, CDK1/cyclin B phosphorylates the SUMOylation machinery component
Ubc9, but not SAE1/SAE2 or SUMO1. Third, CDK1/cyclin B-phosphorylated Ubc9 exhibits increased SUMOylation activity and
elevated accumulation of the Ubc9-SUMO1 thioester conjugate. Fourth, CDK1/cyclin B enhances SUMOylation activity
through phosphorylation of Ubc9 at serine 71. These studies demonstrate for the first time that the cell cycle-specific kinase
CDK1/cyclin B phosphorylates a SUMOylation machinery component to increase its overall SUMOylation activity, suggesting
that SUMOylation is part of the cell cycle program orchestrated by CDK1 through Ubc9.
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Introduction
SUMOylation, a dynamic post-translational modification pro-
cess, requires E1 (SAE1/SAE2), E2 (Ubc9) and multiple E3s (e.g.
Siz and PIAS in vertebrates) to carry out covalent conjugation of
SUMO (e.g. SUMO1, SUMO2 and SUMO3 in mammalian cells)
to target proteins, and a number of de-SUMOylation enzymes (i.e.
Ulp/SENPs) for rapid deconjugation [1]. Like other post-
translational modifications, SUMOylation has been shown to be
involved in many cellular processes [1]. Particularly, there is
increasing evidence supporting a major role of SUMOylation in
mitosis [2,3].
Studies of a temperature-sensitive mutant in budding yeast have
demonstrated that Ubc9 is required for progression through
mitosis [4]. Ubc9 (Hus5) mutants in fission yeast also display
defects during chromosome segregation and reduced cellular
growth [5,6]. Loss of Ubc9 in mouse embryos causes chromosome
mis-segregation and loss of nuclear integrity [6]. Studies in Zebra
fish have also suggested an in vivo requirement of Ubc9 for G2/M
transition and/or progression through mitosis during vertebrate
organogenesis [7].
Studies of other SUMOylation machinery components have
suggested a similar role of SUMOylation in cell cycle progression
through mitosis. In budding yeast, temperature sensitive Smt3
(budding yeast SUMO) mutants show defects in chromosome
segregation [8]. In fission yeast, pmt3D cells also show defects in
mitotic chromosome structure or segregation errors [9]. These
defects include high frequency loss of mini-chromosomes and a cut
(cell untimely torn) phenotype. It has also been demonstrated that
SUMO-1 targets RanGAP1 to kinetochores and mitotic spindles
[10]. In addition to Ubc9 and SUMO, SUMO proteases have also
been shown to play an important role in mitosis as budding yeast
ulp1 mutants show cell cycle delays at the G2/M boundary and
elevated chromosome mis-segregation [11]. In addition to the
genetic analysis, biochemical studies have also demonstrated that
key chromosome structural components (i.e. condensin and
cohesin complexes, and DNA topoisomerase II) are mitotic
SUMOylation targets [2,12–15]. Condensin and cohesin contain
Structural Maintenance of Chromosomes (SMC) proteins [16].
SMC proteins such as Smc1p, Smc3p, Smc5p have been identified
as SUMOylation targets in budding yeast via proteomic screens
[12,14]. topoisomerase II has been shown to be a major target of
SUMOylation in both budding yeast and vertebrates [2,13,15].
SUMOylation of topoisomerase II has been shown to play a key
role in centrosome cohesion and chromosome segregation [2,13].
Expression of the SUMO-null form of Aurora B also results in
abnormal chromosome segregation and cytokinesis failure [3].
Cyclin-dependent kinases (Cdks) are master regulators for cell
cycle progression [17]. Cdks associate with distinct cyclins to
activate its phosphorylation activity. At least 4 interphase Cdks
(Cdk2, Cdk3, Cdk4 and Cdk6) are required to drive cells through
interphase, while CDK1 functions primarily to drive mitosis in
mammalian cells. Cyclin B is known to associate with CDK1 to
drive G2/M transition and progression through mitosis, as
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34250evidenced by its involvement in chromosomal condensation,
nuclear envelope breakdown, centrosome separation and mitotic
exit [18–21]. The central role of CDK1/cyclin B in regulating
mitosis has prompted us to investigate a possible link between
CDK1/cyclin B and SUMOylation.
In the current studies, we have studied the possible interplay
between the master mitotic kinase CDK1/cyclin B and SUMOy-
lation. We show that CDK1/cyclin B, but not many other cell
cycle kinases, enhances sumoylation activity. In addition, CDK1/
cyclin B specifically phosphorylates Ubc9 at serine 71, but not
other SUMO machinery components such as SAE1/SAE2 and
SUMO1. Most importantly, CDK1/cyclin B-mediated phosphor-
ylation of Ubc9 leads to elevated SUMOylation activity and
stimulates the formation of the Ubc9-SUMO1 thioester conjugate.
In the aggregate, these results suggest that Ubc9 phosphorylation
and hence elevated SUMOylation may be part of the cell cycle
regulatory program orchestrated by CDK1/cyclin B.
Results
CDK1/cyclin B Stimulates SUMOylation In vitro
In order to gain a better insight into the link between cell cycle
progression and SUMOylation, we have tested the effect of various
cell cycle kinases (i.e. CDK1/cyclin B, CDK2/cyclin E, PKA,
ERK1, ERK2 and JNK2/SAPK1) on SUMOylation in an in vitro
system (see Materials and Methods). In addition to His6-SUMO1,
His6-Ubc9, SAE1/His6-SAE2, the in vitro SUMOylation system
also included an artificial substrate, GST-hTOP1
(110–125) AA
which contained a single SUMOylation motif of human
topoisomerase I (hTOP1) fused with GST [22]. Serine 112 (a
reported target of CDK1/cyclin B) and serine 111 of GST-
hTOP1
(110–125) were mutated to alanine [23]. Addition of CDK1/
cyclin B was shown to enhance SUMOylation in a concentration-
dependent manner (Figure 1A). The effect of CDK1/cyclin B on
SUMOylation appeared specific since many other cell cycle
kinases, CDK2/cyclin E, ERK1, ERK2, PKA and JNK2/
SAPK1, failed to significantly stimulate SUMOylation in the
same concentration range (Figure 1B-F). It is noted, however,
that ERK1 and ERK2 exhibited an observable but weak
stimulatory activity (Figure 1C-D). Under our in vitro SUMOyla-
tion assay conditions, all kinases were able to phosphorylate their
specific target proteins, indicating their normal phosphorylation
activity (Figure S1; Text S1).
CDK1/cyclin B Specifically Phosphorylates the
SUMOylation Machinery Component Ubc9
The stimulatory activity of CDK1/cyclin B on in vitro
SUMOylation could possibly be related to its kinase activity. To
test this possibility, the CDK1/cyclin B-mediated phosphorylation
of the SUMO machinery components (SAE1/SAE2, SUMO1
and/or Ubc9) was investigated in vitro in the presence of [c-
32P]
ATP (see Methods and Materials). As shown in Figure 2A,
CDK1/cyclin B was shown to cause an observable, but relatively
weak, increase in the radio-labeling of His6-SAE1 and His6-SAE2
(Figure 2A). However, the radio-labeling exhibited a low
background in the absence of CDK1/cyclin B. CDK1/cyclin B
did not cause any detectable phosphorylation of His6-SUMO1 in
the same CDK1/cyclin B concentration range (Figure 2B). By
contrast, CDK1/cyclin B caused a concentration-dependent
increase of phosphorylated His6-Ubc9 as evidenced by the
appearance of a radio-labeled band (revealed by autoradiography)
with the same mobility as His6-Ubc9 band (as revealed by the
corresponding coomassie-stained band) (Figure 2C). On the
other hand, SUMOylatable substrate GST-hTOP1
(110–125)AA was
unaffected by the stimulatory effect of CDK1/cyclin B
(Figure 2D). Histone H1, a known CDKs target protein, was
strongly phosphorylated by CDK1/cyclin B, illustrating the
normal activity of CDK1/cyclin B (Figure S2; Text S1).
Collectively, these observations suggest that Ubc9 is the only
SUMO machinery component to be significantly phosphorylated
by CDK1/cyclin B.
CDK1/cyclin B-phosphorylated Ubc9 Exhibits Elevated
SUMOylation Activity
To prove that CDK1/cyclin B-mediated phosphorylation of
Ubc9 is responsible for the observed stimulatory effect of CDK1/
cyclin B on SUMOylation in vitro, His6-Ubc9 was pretreated with
GST-CDK1/cyclin B in the presence or absence of ATP. After
pretreatment, the reaction mixtures were passed through gluta-
thione sepharose three times to remove GST-tagged CDK1/cyclin
B( Figure 3A). The flow-through fraction 3 (FT3) of phosphor-
ylated and non-phosphorylated His6-Ubc9 were subjected to in
vitro SUMOylation assay. As shown in Figure 3B, phosphorylated
His6-Ubc9 exhibited elevated (about 2-fold) SUMOylation activity
as compared to non-phosphorylated His6-Ubc9 (Figure 3B;
upper panel). The loading amount of both forms of Ubc9s were
relatively equal (Figure 3B; lower panel). These results suggest
that the SUMOylation-stimulatory activity of CDK1/cyclin B is at
least in part mediated through its phosphorylation of Ubc9.
CDK1/cyclin B upregulates SUMOylation by Increasing
Thioester Bond Formation between Phosphorylated
Ubc9 and SUMO1 but not between SAE1/SAE2 and
SUMO1
SUMO1 conjugates to E1 activating enzyme (SAE1/SAE2)
throughthioesterbondlinkage;whereas,SUMO1conjugatesUbc9
through thioester and isopeptide bond linkage in the SUMOylation
pathway. To examine whether CDK1/cyclin B stimulates SU-
MOylation through SUMO1 activation of SAE1/SAE2 (in
thioester linkage), the SAE1/His6-SAE2 and His6-SUMO1 were
mixed together with increased concentration of CDK1/cyclin B.
Result showed that increasing concentration of CDK1/cyclin B did
not alter the thioester bond formation between His6-SUMO1 and
SAE1/His6-SAE2 (Figure 4A), suggesting that the activation of
SUMO1bySAE1/SAE2isirrelevanttoCDK1/cyclinBtreatment.
To examine whether CDK1/cyclin B increases SUMOylation
through conjugational activity of phosphorylated Ubc9 (in thioester
linkage). His6-Ubc9, SAE1/His6-SAE2 and His6-SUMO1 were
mixedtogetherwithincreasedconcentrationofGST-CDK1/cyclin
B in the presence or absence of 200 mM DTT. In the non-reduced
condition, three different molecular species containing SUMO
conjugations in the form of isopeptide and thioester bond were
observed. The summation of thioester and isopeptide bond
conjugates was greater than the isopeptide bond conjugates as
shown in Figure 4C. Moreover, the intensity of the summation of
thioesterandisopeptidebondconjugateswasstronglyenhancedina
concentration-dependent manner by increased concentration of
CDK1/cyclin B (Figure 4B). However, due to isopeptide bond
formation was not affected by CDK1/cyclin B as shown in
Figure 4C, therefore, we conclude that thioester bond conjugates
was enhanced by CDK1/cyclin B. In the reducing condition, an
observation of at least two different molecular species containing
either one or two SUMO conjugations in the form of isopeptide
bond were observed. This observation agrees with the report that
Ubc9 contains multiple SUMO conjugation sites [24,25]. More-
over, the isopeptide bond conjugations were not enhanced by the
increasedconcentrationofCDK1/cyclinB,suggestingthatCDK1/
Cdk1 Phosphorylation and Stimulation of Ubc9
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34250Figure 1. CDK1/cyclin B stimulates SUMOylation in vitro. (A-F) Various concentrations of different recombinant kinases, CDK1/cyclin B (6 nM,
12 nM and 30 nM), CDK2/cyclin E (5 nM, 9 nM and 23 nM), ERK1 (7 nM, 14 nM and 35 nM), ERK2 (7 nM, 15 nM and 37 nM), PKA (12 nM, 24 nM and
61 nM) and JNK2/SAPK1 (11 nM, 22 nM and 56 nM), were added to in vitro SUMOylation reaction mixtures containing His6-SUMO1, His6-Ubc9, SAE1/
His6-SAE2, GST-hTOP1
(110–125) AA and ATP at 37uC for 60 min. The reactions were then boiled in SDS sample buffer and analyzed by 15% SDS-PAGE,
followed by immunoblotting with anti-GST antibody.
doi:10.1371/journal.pone.0034250.g001
Cdk1 Phosphorylation and Stimulation of Ubc9
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34250cyclin B does not affect the isopeptide bond formation between
phosphorylated His6-Ubc9 and His6-SUMO1 (Figure 4C). Alto-
gether, results strongly suggest that CDK1/cyclin B affects Ubc9
function by phosphorylating Ubc9, therefore facilitates and
increases thioester bond formation between phosphorylated Ubc9
and SUMO1, ultimately upregulates SUMOylation activity of
substrate protein. Additionally, CDK1/cyclin B neither phosphor-
ylatesSAE1/SAE2norenhancesthioesterbondformationbetween
SUMO1 and SAE1/SAE2 enzyme.
CDK1/cyclin B-phosphorylated Ubc9 Stimulates Multi-
SUMOylation of Full-length Human Topoisomerase I
Full-length human topoisomerase I (hTOP1), a cell cycle-
regulated protein, contains multiple SUMOylation sites at its N-
terminus [25,22,26]. Multi-SUMOylation of hTOP1 at its N-
terminus occurs both in vivo and in vitro [25,22,26]. hTOP1 also
contains multiple phosphorylation sites at its N-terminus including
the Ser-112 phosphorylation site that is phosphorylated by
CDK1/cyclin B [23]. We therefore sought to determine whether
CDK1/cyclin B stimulates multi-SUMOylation of hTOP1 in vitro
and whether CDK1/cyclin B-phosphorylated Ubc9 is responsible
for the stimulation. The substrate used in the in vitro system is
hTOP1. As shown in Figure 5A, CDK1/cyclin B stimulated the
formation of multiple high molecular weight species of hTOP1,
representing hTOP1 conjugates with one, two and three
conjugated SUMO1, suggesting that CDK1/cyclin B stimulates
multi-SUMOylation of hTOP1 (Figure 5A). We have also
investigated the effect of CDK1/cyclin B-phosphorylated Ubc9
on multi-SUMOylation of hTOP1 using GST-hTOP1
(1–200) as
substrate. As shown in left panel of Figure 5B, unphosphorylated
Ubc9 stimulated multi-SUMOylation of GST-hTOP1
1–200 as
compared to the control (no Ubc9). Importantly, multi-SUMOy-
Figure 2. CDK1/cyclin B phosphorylates Ubc9 in vitro. (A)InvitrophosphorylationofSAE1/SAE2byCDK1/cyclinB.CDK1/cyclinB(3 nM,6 nMand
12 nM)wasincubatedwith(left)orwithout(right)SAE1/His6-SAE2for30 minat30uCinthepresenceof[c-
32P]ATP.Thereactionswereanalyzedby10%
SDS-PAGE followed by Coomassie blue staining and autoradiography. (B) In vitro phosphorylation of His6-SUMO1 by CDK1/cyclin B. Various
concentrationsofCDK1/cyclinB(asmentionedabove)wereincubatedwith(left)orwithoutHis6-SUMO1(right)inthepresenceof[c-
32P]ATPfor30 min
at 30uC. (C) In vitro phosphorylation of Ubc9 by CDK1/cyclin B. Various concentrations of CDK1/cyclin B (as mentioned above) were incubated with (left
panel)orwithoutHis6-Ubc9(rightpanel)inthepresenceof[c-
32P]ATPfor30 minat30uC.(D)InvitrophosphorylationofGST-hTOP1
(110–125)AA.Various
concentrationsof CDK1/cyclinB(asmentionedabove)wereincubatedwith(left)orwithoutGST-hTOP1
(110–125)AA(right)in thepresenceof [c-
32P]ATP.
Reaction mixtures of B, C and D were analyzed by 15% SDS-PAGE followed by Coomassie blue staining and autoradiography.
doi:10.1371/journal.pone.0034250.g002
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(1–200) was further stimulated when Ubc9
(E2) was replaced with CDK1/cyclin B-phosphorylated Ubc9 (P-
E2) (Figure 5B; left panel). Higher molecular weight SUMO1-
modified species of GST-hTOP1
(1–200) were observed together
with a concomitant decrease in the level of unmodified GST-
hTOP1
(1–200) (Figure 5B; left panel). Because the intensity of
Ubc9 and phosphorylated Ubc9 after immunoblotting with anti-
Ubc9 antibody is almost the same, which is consistent with Biorad
protein assay, thus we use Ubc9 and phosphorylated Ubc9 for
SUMOylation assay at a final concentration of 6 mM( Figure 5B;
right panel). These results suggest that CDK1/cyclin B-
stimulated multi-SUMOylation of hTOP1 is also likely to be
mediated through phosphorylated Ubc9, which provides addi-
tional evidence for the possible physiological relevance of CDK1/
cyclin B-mediated phosphorylation of Ubc9 in stimulation of
SUMOylation.
Figure 3. CDK1/cyclin B-phosphorylated Ubc9 exhibits elevated SUMOylation activity. (A) Purified His6-Ubc9 was incubated with GST-
CDK1/cyclin B in the presence or absence of ATP for 30 min at 30uC. The GST-CDK1/cyclin B was then removed by passing through glutathione
sepharose. The bound fraction of glutathione sepharose (contains phosphorylated Ubc9) and flow through fractions (FT, FT2, FT3) were analyzed by
12.5% SDS-PAGE, followed by immunoblotting with anti-GST and anti-Ubc9 antibody. (B) 3 mM, 6 mM and 12 mM of phosphorylated Ubc9 (flow
through fraction 3) and non-phosphorylated Ubc9 (flow through fraction 3) were individually incubated with His6-SUMO1, SAE1/His6-SAE2, GST-
hTOP1
(110–125) and ATP for 60 min at 37uC. The SUMOylation reaction mixtures were then analyzed by 15% SDS-PAGE, followed by immunoblotting
with anti-GST antibody. The amount of phosphorylated and non-phosphorylated Ubc9 for SUMOylation assay were detected by immunoblotting
with anti-Ubc9 antibody.
doi:10.1371/journal.pone.0034250.g003
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Serine 71
In order to identify the phosphorylation sites of Ubc9, in vitro
phosphorylatedaswellasnon-phosphorylated Ubc9was firsttryptic
digested and phosphopeptides were enriched by immobilized metal
affinity chromatography (IMAC). Enriched phosphopeptides were
then subjectedto liquid chromatography coupled withtandem mass
spectrometry (LC-MS/MS). As shown in Figure 6, the MS/MS
analysis revealed a phosphorylation site at serine 71 in a peptide
corresponding to residues MLFKDDYPSpSPPK of Ubc9, whereas
no phosphorylation was detected at serine 70 (Figure 6). The
detection of b9 ions, with no neutral loss, indicates that the site of
Figure 4. CDK1/cyclin B upregulates SUMOylation by increasing thioester bond formation between phosphorylated Ubc9 and
SUMO1 but not between SAE1/SAE2 and SUMO1. (A) To examine the thioester bond formation between His6-SUMO1 and SAE1/His6-SAE2,
purified His6-SUMO1 and SAE1/His6-SAE2 were incubated with various concentrations of CDK1/cyclin B (1.5 nM, 3 nM and 6 nM) in the presence or
absence of ATP. Reaction mixtures were run on a 10% SDS-PAGE and immunoblotted with anti-SAE1/SAE2 antibody. (B) Ubc9 thioester conjugation
assaywasperformedbyincubatingpurifiedHis6-Ubc9,SAE1/His6-SAE2andHis6-SUMO1withvariousconcentrationsofCDK1/cyclinB(1.2 nM,3 nMand
6 nM) in the presence of ATP for 60 min at 37uC. Samples were then resolved on a 15% SDS-PAGE and probed with anti-Ubc9 antibody. (C) Ubc9
thioesterconjugationassayinwas performedsimilarasin(B),butatthe endofthereaction,200 mMofDTTwas addedtosamplesforovernight at40uC.
The reduced samples were run on a 15% SDS-PAGE, followed by immunoblotting with anti-Ubc9 antibody. Iso, isopeptide bond; Thiol, thioester bond.
doi:10.1371/journal.pone.0034250.g004
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through the detection of y4-98 and b10-98 ions. In addition the
phosphate fingerprint of the neutral loss (owing to H3PO4) from the
parentionisalsoapositivesignalofphosphorylation.Incomparison
to the negative control, no phosphorylated amino acid residue was
detected (Figure S3). Overall, these results suggest that Cdk1/
cyclin B mediates the phosphorylation of Ubc9 at serine 71.
CDK1/cyclin B Enhances SUMOylation Activity through
Wild Type Ubc9 but not Mutant Ubc9
To determine whether serine 71 plays a role in regulating
SUMOylation of Ubc9, serine 70 and serine 71 were mutated to
alanine (S70A/S71A), followed by assaying SUMOylation in vitro.
As predicted, the SUMOylation activity driven by wild-type Ubc9
was enhanced in the presence of CDK1/cyclin B (Figure 7). By
contrast, SUMOylation activity driven by S70A/S71A mutant
Ubc9 was not affected by the addition of CDK1/cyclin B,
suggesting that CDK1/cyclin B regulates SUMOylation activity
through phosphorylating serine 71 of Ubc9.
Discussion
The crosstalk between cell cycle and SUMOylation has been
widely studied. Our demonstration that CDK1/cyclin B stimulates
SUMOylation in vitro could indicate a potential molecular link for
the crosstalk. CDK1/cyclin B could stimulate SUMOylation
through phosphorylation of SUMO target proteins, SUMO
machinery components, or a combination of both. In our studies,
CDK1/cyclin B was shown to phosphorylate Ubc9 but not
SUMO1 or SAE1/SAE2 (Figure 2). Our results agree in part
with the findings that SUMO machinery components can be
phosphorylated and SUMOylated in vivo [24,27]. More impor-
tantly, phosphorylation of Ubc9 by CDK1/cyclin B, as demon-
strated in our studies, is a novel finding which could have broad
implications in cell cycle regulation. Specifically, phosphorylation
Figure 5. CDK1/cyclin B enhances SUMOylation level of human TOP1 containing multiple SUMO conjugation site. (A) Full-length
protein of human topoisomerase I was incubated with His6-SUMO1, His6-Ubc9, SAE1/His-SAE2 and ATP in the presence of 6, 12, 30 and 60 nM of
CDK1/cyclin B. The reaction was resolved on a 6% SDS-PAGE and immunoblotted with anti-topoisomerase I antibody. (B) Equal amount of CDK1/
cyclin B phosphorylated Ubc9 (P-E2) and Ubc9 (E2) (6 mM at the final concentration) was individually incubated with His6-SUMO1, SAE1/His6-SAE2,
GST-hTOP1
(1–200) and ATP at 37uC for 30 min, 60 min and 120 min. The resulting SUMOylation reaction mixtures were run on a 8% SDS-PAGE,
followed by immunoblotting with anti-topoisomerase I antibody. The amount of phosphorylated Ubc9 (P-E2) and Ubc9 (E2) for SUMOylation assay in
Fig. 5B was determined by immunoblotting with anti-Ubc9 antibody. Lane 1 and 3 (right panel) were loaded with 1 mg Ubc9 and phosphorylated
Ubc9, respectively. Lane 2 and lane 4 (right panel) were loaded with 2 mg of Ubc9 and phosphorylated Ubc9, respectively.
doi:10.1371/journal.pone.0034250.g005
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orchestrated by CDK1/cyclin B.
It is more difficult to determine whether CDK1/cyclin B can
also stimulate SUMOylation through its phosphorylation of the
SUMO substrate. Hackbarth et al suggested that human
topoisomerase I contains an in vivo phosphorylation site (Ser-112)
regulated by CDK1/cyclin B [23]. In our studies, we have
confirmed that CDK1/cyclin B indeed phosphorylates GST-
hTOP1
(110–125) but not GST-hTOP1
(110–125)AA mutant (Ser 111
and Ser 112 converted to Ala 111 and Ala 112). However,
CDK1/cyclin B stimulates SUMOylation of both GST-
hTOP1
(110–125) and GST-hTOP1
(110–125)AA mutant to the same
extent. These results strongly suggest that the SUMOylation-
stimulatory effect of CDK1/cyclin B is due to CDK1/cyclin B-
mediated phosphorylation of the SUMOylation machinery (i.e.
Ubc9) rather than that of the SUMO substrate (i.e. GST-
hTOP1
(110–125)) in this in vitro system. We have also performed in
vitro SUMOylation assay using a more physiologically relevant
substrate, GST-hTOP1
(1–200), which contains the entire N-
terminus of hTOP1. The N-terminus of hTOP1, which contains
multiple CDK1/cyclin B phosphorylation sites, is known to be
multi-SUMOylated in vivo [22,26]. Indeed, CDK1/cyclin B
stimulates multi-SUMOylation of GST-hTOP1
(1–200) in our in
vitro system. More importantly, CDK1/cyclin B-phosphorylated
Ubc9 is much more efficient than unphosphorylated Ubc9 in
stimulating multi-SUMOylation of GST-hTOP1
(1–200). These
results suggest the SUMOylation-stimulatory effect of CDK1/
cyclin B is primarily due to its phosphorylation of the SUMOyla-
tion machinery (i.e. Ubc9). However, we cannot rule out the
possibility that CDK1/cyclin B may also stimulate SUMOylation
through its phosphorylation of GST-hTOP1
(1–200).
The function of Ubc9 is to conjugate SUMO1 received from
SAE1/SAE2. The conjugation requires formation of thioester
bond. According to Knipscheer et al., Ubc9 is autoSUMOylated
thereby leads to target discrimination in the following SUMO
modification, suggesting that Ubc9 itself serves as a substrate and
forms isopeptide bond with SUMO on specific lysine [24]. This
raises a question whether CDK1/cyclin B enhances thioester
bond conjugational activity of Ubc9 with SUMO1 or enhances
isopeptide bond linkage of SUMO1 with Ubc9 or substrate
protein. Our study showed that the isopeptide bond linkage
between CDK1/cyclin B phosphorylated Ubc9 and SUMO1 was
Figure 6. CDK1/cyclin B mediates phopshorylation of Ubc9 at Serine 71. IMAC enriched tryptic peptides of Ubc9 were detected by CID
tandem mass spectra. Precursor ion m/z 802.8 (charge state +2) representing the phosphopeptide MLFKDDYPSpSPPK. Residues bearing phosphate
moieties are indicated with p. ‘‘b’’ and ‘‘y’’ ions series represent fragment ions containing the N- and C-termini of the peptide, respectively. Product
ions marked with * resulted from elimination of NH3. The mass of 98 on the peaks was derived from neutral losses (-97.9769 Da) of phosphoric acid
(H3PO4).
doi:10.1371/journal.pone.0034250.g006
Figure 7. CDK1/cyclin B enhances SUMOylation activity
through wild type Ubc9 but not mutant Ubc9 S70A/S71A.
Same amount of wild-type and mutant (S70A/S71A) of Ubc9 (at a
concentration of 6 mM) was individually added to in vitro SUMOylation
reaction mixtures containing His6-SUMO1, SAE1/His6-SAE2, GST-hTOP1
(110–125) AA and ATP in the presence of CDK1/cyclin B (6 nM and 12 nM)
at 37uC for 60 min. The reactions were then boiled in SDS sample buffer
and analyzed by 15% SDS-PAGE, followed by immunoblotting with anti-
GST antibody.
doi:10.1371/journal.pone.0034250.g007
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summation of thioester and isopeptide bond formation between
CDK1/cyclin B phosphorylated Ubc9 and SUMO1 was
increased in a concentration-dependent manner in non-reduced
condition (Figure 4B). Because isopeptide bond formation was
unaffected by CDK1/cyclin B illustrated in reduced condition,
thus thioester bond formation was the only covalent bond to be
increased by CDK1/cyclin B. As the amount of thioester bond
formation reflects the conjugational capacity of Ubc9, our in vitro
results clearly indicate that the SUMOylation activity in cell
cycle is upregulated when Ubc9 is phosphorylated by CDK1/
cyclin B, in addition, the upregulation of SUMOylation activity
is directed by increased conjugational activity of phosphorylated
Ubc9.
The crosstalk between phosphorylation and SUMOylation has
been widely studied in recent years. Notably, many SUMO
substrates contain a highly conserved motif having a SUMO
consensus site and a proline-directed phosphorylation site
(YKxExxSP) leading to a concept of phosphorylation-dependent
SUMO modification (PDSM) [28]. Thus, phosphorylation has
widely been accepted to serve as a regulator for SUMOylation at
the substrate level. On the other hand, recent studies have pointed
to the possibility that the SUMOylation machinery components
may be subject to post-translational modifications. For example,
SUMO1 itself has been shown to be phosphorylated in vivo by
using mass spectrometric approach and Ubc9 is itself SUMO-
modified which results in alteration of SUMO target specificity
[24,27]. Our current studies have demonstrated that CDK1/
cyclin B can phosphorylate the SUMOylation machinery
component Ubc9, adding new evidence for regulation of
SUMOylation at the level of SUMOylation machinery.
While our studies implicate Ubc9 phosphorylation and hence
SUMOylation to be part of the mitosis regulatory program
orchestrated by CDK1/cyclin B, SUMOylation has also been
implicated in the regulation other cell cycle phases. For example,
SUMO modification of retinoblastoma (Rb) leads to the release of
repressive activity of Rb on the E2F transcription factor, resulting
in G1/S transition [29]. p73, a member of the p53 family, is
SUMO-modified via binding to PIAS-1 during the S phase
[30,31]. Interestingly, CDK1, by partnering with other cyclins, is
also known to regulate other cell cycle phases [32,17]. Therefore,
it seems plausible that CDK1, by partnering with different cyclins,
could also phosphorylate Ubc9 to enhance its SUMOylation
activity that may contribute cell cycle progression at other phases
of the cell cycle. Clearly, further studies are necessary to establish
the role of Ubc9 phosphorylation in SUMOylation regulation
during the cell cycle.
Materials and Methods
Plasmid Constructs
Plasmids encoding amino acids 1–97 of SUMO1 (pQE30-
SUMO1
(1–97)), full-length Ubc9 (pQE30-Ubc9), full-length SAE1,
full-length SAE2 and full-length human topoisomerase I (hTOP1)
have been described previously [22]. DNA encoding hTOP1
fragments which contained single and multiple SUMOylation
motifs were subcloned into Glutathione S-transferase (GST) fusion
protein Escherichia coli expression vector, pGEX-KG [33]. The
resulting plasmids are designated pGEX-hTOP1
(110–125) and
pGEX-hTOP1
(1–200), respectively. Plasmid expressing pGEX-
hTOP1
(110–125)AA (Ser 111 and Ser 112 are mutated to Ala 111
and Ala 112, respectively) and plasmid expressing pQE30-Ubc9
S70A/S71A (Ser70 and Ser 71 are mutated to Ala 70 and Ala 71,
respectively) were also generated using QuickChange site-directed
mutagenesis kit (Stratagene).
Cell Culture
Spodoptera frugiperda Sf21 insect cells (Invitrogen) for the
expression of E1 (SAE1/His6-SAE2) and full-length hTOP1 were
cultured at 27uC in Grace’s medium (Invitrogen) supplemented
with 0.33% tissue culture yeastolate (Sigma), 0.33% tissue culture
lactalbumin hydrolysate (Sigma), 3% fetal bovine serum and
penicillin/streptomycin.
Protein Expression and Purification
For the expression of SUMO1 and Ubc9, plasmids pQE30-
SUMO1
(1–97) and, pQE30-Ubc9 and pQE30-Ubc9 S70A/S71A
were transformed into E.coli TOP10 strain. The detailed
procedure for expression and purification has been described
previously [22]. pGEX-hTOP1
(110–125), pGEX-hTOP1
(1–200) and
pGEX-hTOP1
(110–125) AA were individually transformed into
E.coli TOP10 strain. Transformants were inoculated into LB broth
containing ampicillin (50 g/ml). Isopropyl b-D-1-thiogalactopyr-
anoside (IPTG) was added to a final concentration of 0.4 mM,
when A600 nm reached OD 0.3. The culture was incubated for
another 2h at 37uC. Cells were centrifuged at 4000 xg for 30 min
and resuspended in 1x PBS buffer (140 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3). 1 mM PMSF and
1 mg/ml lysozyme were added to cell suspensions followed by
sonication. Cell lysates were then centrifuged at 13,000 xg for
30 min. Supernatants were passed through the Glutathione
Sepharose 4B column (bed volume, 1 ml). Nonspecific proteins
were washed out with 1 x PBS multiple times until no protein was
detected by Biorad protein assay. GST-hTOP1
(110–125) and GST-
hTOP1
(110–125)AA were individually eluted with glutathione
elution buffer (50 mM Tris-HCl, pH 7.4; 10 mM reduced
glutathione, pH 8.0). For baculovirus expression and purification,
recombinant SAE1/His6-SAE2 and full-length hTOP1 were
expressed and purified as described previously [22].
In vitro SUMOylation Assays
To study the effect of various kinases on SUMOylation, His6-
SUMO1 (1 mg), His6-Ubc9 (1 mg), SAE1/His6-SAE2 (100 ng),
substrate protein [GST-hTOP1
(110–125), GST-hTOP1
(1–200), GST-
hTOP1
(110–125)AA or full-length hTOP1 (0.5 mg)], ATP (5 mM)
and SUMO reaction buffer (20 mM HEPES, pH 7.5; 5 mM
MgCl2) were mixed together in a total reaction volume of 20 ml.
The reaction mixtures were incubated with various concentrations
of individual recombinant kinases such as CDK1/cyclin B (6 nM,
12 nM and 30 nM) (Cell Signaling Technology & New England
Biolabs), CDK2/cyclin E (5 nM, 9 nM and 23 nM) (Cell
Signaling Technology), ERK1 (7 nM, 14 nM and 35 nM) and
ERK2 (7 nM, 15 nM and 37 nM) (Millipore) and JNK2/SAPK1
(11 nM, 22 nM and 56 nM) (Millipore) at 37uC for 60 min,
followed by boiling in SDS sample buffer for 10 min. Samples
were then analyzed by SDS-PAGE and immunoblotted with goat
anti-GST antibody (Santa Cruz) or anti-topoisomerase I antibody
(LAE Biotech).
To study the concentration-dependent effect of phosphorylated
Ubc9 on SUMOylation activity, GST-hTOP1
(110–125) (0.5 mg) was
incubated with His6-SUMO1 (1 mg), SAE1/His6-SAE2 (100 ng),
ATP (5 mM) and reaction buffer (20 mM HEPES, pH 7.5, 5 mM
MgCl2) in the presence of increasing concentrations of phosphor-
ylated or non-phosphorylated Ubc9 (3 mM, 6 mM and 12 mM) in a
total volume of 20 ml. The reaction mixture was incubated at 37uC
for 60 min and then boiled in SDS sample buffer for 10 min. To
study the time course effect, GST-hTOP1
(1–200) (0.5 mg) was
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ATP (5 mM) and reaction buffer (20 mM HEPES, pH 7.5, 5 mM
MgCl2) in the presence of phosphorylated or non-phosphorylated
Ubc9 (6 mM). The reaction mixture was incubated at 37uC for
three various time points (30 min, 60 min and 120 min), followed
by boiling in SDS sample buffer for 10 min. All heat-denatured
samples were analyzed by SDS-PAGE and immunoblotted with
goat anti-GST antibody (Santa Cruz) or anti-topoisomerase I
antibody (LAE Biotech).
To study if Cdk1/cyclin B affects SUMOylation driven by
mutant Ubc9, wild type or S70A/S71A mutant Ubc9 (6 mMa t
final concentration) was incubated with His6-SUMO1 (1 mg),
SAE1/His6-SAE2 (100 ng), GST-hTOP1
(110–125)AA, ATP
(5 mM) and SUMO reaction buffer (20 mM HEPES, pH 7.5;
5 mM MgCl2) in the presence of CDK1/cyclin B (6 nM and
12 nM) (New England Biolabs) in a total reaction volume of 20 ml
at 37uC for 60 min.
In vitro Phosphorylation Assays
The phosphorylation assay was performed in 20 ml of reaction
mixtures. SAE1/His6-SAE2 (1 mg) was incubated with various
concentrations (3 nM, 6 nM and 12 nM) of CDK1/cyclin B in the
presence of [c-
32P] ATP (0.05 mCi/ml) in Protein kinase buffer
provided by supplier (New England Biolabs). CDK1/cyclin B
(3 nM, 6 nM and 12 nM) were also incubated with [c-
32P] ATP
(0.05 mCi/ml) in protein kinase buffer in the presence or absence of
His6-SUMO1 (1 mg), His6-Ubc9 (1 mg) or GST-hTOP1
(110–125)
AA (1 mg). All reaction mixtures were incubated at 30uC for
30 min and boiled in SDS sample buffer for 10 min. Samples were
then analyzed by SDS-PAGE followed by Coomassie blue staining
and autoradiography.
Isolation of Phosphorylated Ubc9
GST-CDK1/cyclin B from Cell Signaling Technology (35 nM)
was incubated with His6-Ubc9 (10 mg) in a 200 ml phosphorylation
reaction mixture containing CDK1/cyclin B kinase buffer in the
presence or absence of ATP (5 mM) at 30uC for 30 min. The
reaction mixture was passed through Glutathione sepharose 4B
(200 ml bed volume) to remove the GST-tagged CDK1/cyclin B
from the mixture. For checking the integrity of phosphorylated
Ubc9, the flow-through was analyzed by SDS-PAGE and
immunoblotted with goat anti-GST (GE Healthcare) and goat
anti-Ubc9 antibodies (Santa Cruz).
Thioester Conjugation Assay
To examine whether CDK1/cyclin B affects thioester bond
formation between SUMO1 and SAE1/SAE2, reaction mixture
containing His6-SUMO1 (1 mg), SAE1/His6-SAE2 (100 ng),
SUMO reaction buffer (20 mM HEPES, pH 7.5; 5 mM MgCl2)
and ATP (5 mM) were incubated with various concentrations
(1.5 nM, 3 nM and 6 nM) of CDK1/cyclin B in a total volume of
20 mla t3 7 uC for 60 min. Reactions were heat-denatured with
sample buffer without ß-mercaptoethanol or DTT for 10 min and
resolved on SDS-PAGE and immunoblotting with rabbit anti-
SAE1/SAE2 antibody.
To examine whether thioester conjugational activity of Ubc9 is
affected by CDK1/cyclin B, reaction mixture containing His6-
Ubc9 (1 mg), His6-SUMO1 (1 mg) and SAE1/His6-SAE2 (100 ng)
were incubated with increased concentration (1.2 nM, 3 nM and
6 nM) of CDK1/cyclin B in a total reaction volume of 20 mla t
37uC for 60 min. The reactions were prepared in two sets, one set
of the reaction samples were reduced with DTT (200 mM) and the
other set was remained in non-reduced at 40uC for overnight. The
intramolecular noncovalent bonds of both reaction samples were
heat-denatured for 10 min with urea (8 M) and sample buffer
without ß-mercaptoethanol or DTT. The samples were resolved
on SDS-PAGE and immunoblotted with goat anti-Ubc9 antibody
(Santa Cruz).
In-solution Digestion and Phosphopeptide Enrichment
To identify the phosphorylation site of Ubc9 which is
phosphorylated by CDK1/cyclin B, a solution-based in vitro
phosphorylation of Ubc9 was initially prepared, the end-reaction
of Ubc9 phosphorylation was firstly reduced with 10 mM DTT at
room temperature for 60 min. Alkylation reaction was then
carried out by adding 55 mM iodoacetanide at room temperature
for 20 min. Reduced and alkylated Ubc9 was subsequently
digested with trypsin 37uC overnight. Resulting tryptic Ubc9
phopshopeptides were subjected to phosphopeptide enrichment
procedures supplied by Clontech. Enriched Ubc9 phosphopep-
tides were acidified TFA for further ZipTips
TM desalting
procedure (Millipore).
LC-ESI-MS/MS Analyses
Peptide samples were reconstituted in buffer A (0.1% FA in
H2O) and analyzed on Waters Synapt G2 HDMS (Waters,
Milford, MA). Samples were injected onto a 2 cm6180 mm
capillary trap column and separated on a 75 mm65c m
nanoACQUITY 1.7 mm BEH C18 column using a nanoAC-
QUITY Ultra-Performance LC system (Waters, Milford, MA).
The column was maintained at 35uC and bound peptides were
eluted with a gradient of 5–40% buffer B (buffer A, 0.1% FA in
H2O; buffer B, 0.1% FA in ACN) for 30 min. The MS was
operated in ESI positive V mode with a resolving power of
10000 and calibrated with a synthetic human [Glu1]-Fibrino-
peptide B solution (0.5 pmol/mL, Sigma-Aldrich) delivered
through the NanoLockSpray source. Data acquisition was
performed using data directed analysis (DDA) method. The
DDA method included one full MS scan (m/z 350–1600, 1 s/
scan) and three MS/MS scans (m/z 100–2000, 1 s/scan)
performed sequentially on the three most intense ions present
in the full scan mass spectrum.
Supporting Information
Figure S1 Determination of the phosphorylation activ-
ities of different kinases. Various concentrations of (A)
CDK1/cyclin B (12 nM, 30 nM and 60 nM) or (B) CDK2/cyclin
E (9 nM, 23 nM and 46 nM) were incubated with (left) or without
(right) histone H1 for 30 min at 30uC in the presence of [c-
32P]
ATP. The reactions were analyzed by 12.5% SDS-PAGE followed
by Coomassie blue staining and autoradiography. Various
concentrations of (C) ERK1 (14 nM, 35 nM and 71 nM), (D)
ERK2 (15 nM, 37 nM and 74 nM) or (E) PKA (24 nM, 61 nM
and 122 nM) was incubated with (left) or without (right) myelin
basic protein (MBP) for 30 min at 30uC in the presence of [c-
32P]
ATP. The reactions were analyzed by 15% SDS-PAGE followed
by Coomassie blue staining and autoradiography. Various
concentrations of (F) JNK2/SAPK1 (22 nM, 56 nM and
111 nM) was incubated with (left) or without (right) activating
transcription factor 2 (ATF2) for 30 min at 30uC in the presence of
[c-
32P] ATP. The reaction was analyzed by 10% SDS-PAGE
followed by Coomassie blue staining and autoradiography.
(TIF)
Figure S2 Determination of the phosphorylation activ-
ity of CDK1/cyclin B. Twelve nM of CDK1/cyclin B was
incubated with (left) or without (right) histone H1 for 30 min at
30uC in the presence of [c-
32P] ATP (0.05 mCi/ml). The
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Coomassie blue staining and autoradiography.
(TIF)
Figure S3 Non-phosphorylated Ubc9 as a negative
control analyzed by CID tandem mass spectra. Precursor
ion m/z 508.92 (charge state +3) representing the peptide
MLFKDDYPSSPPK. 0b0 and 0y0 ions series represent fragment
ions containing the N- and C-termini of the peptide, relatively.
(TIF)
Text S1 Supporting methods.
(DOC)
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